Malmö Diet and Cancer Study

https://www.neurodegenerationresearch.eu/survey/malmo-diet-and-cancer-study/

Title of cohort

Malmö Diet and Cancer Study

Acronym for cohort

MDCS

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Olle

Name of Principal Investigator - Last name

Melander

Address of institution -Institution

Dept of Clinical Sciences, Malmö

Address of institution - Street address

Jan Waldenströms gata 35

Address of institution - City

Malmö

Address of institution - Postcode

20502

Country

Sweden

Website

http://www.med.lu.se/klinvetmalmo/befolkningsstudier/malmoe_kost_cancer_och_malmoe_foereb

Contact email

Funding source

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias|Parkinson's disease

Q1b. When are studies on the above condition(s) expected to become possible?

2016-2020

Q2a. In a single sentence what is the stated aim of the cohort?

Original aim was to examine the relationship between diet and the subsequent cancer risk, but was extended to include particularly cardiovascular diseases and diabetes and their risk factors

Q2b. What distinguishes this cohort from other population cohorts?

It is one of the largest prospective cohorts in Sweden, only a few studies in the world have similar data on diet and nutrition. The diagnosis of dementia disorders and Parinsonian disorders has been validated through medical records.

Q3a. i) Number of publications that involve use of your cohort to date

>1000

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

Gustavsson AM, Stomrud E, Abul-Kasim K, Minthon L, Nilsson PM, Hansson O, Nägga K. Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. Cerebrovasc Dis Extra. 2015 May 20;5(2):41-51.

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

44

Q4a. Study criteria: what is the age range of participants at recruitment? To:

73

Q4b. Study criteria: what are the inclusion criteria?

Residents in Malmö, born 1923-1950

Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

More than 15,000 participants

Q6a. Please describe what measures are used to characterise participants

Data are obtained from questionnaries, analyses of blood samples, national and local registers

Q6b. Are there additional measures for participants with a clinical disorder?

Yes, but only in conjunction with the screening

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

Yes

If yes please specify

Primarily cancer, cardiovascular diseases and diabetes, Dementia

Q7. What is the study design (select all that apply)?

Prospective cohort|Longitudinal

Q8. Are your cases matched by

Other health assessment

Q9a. Does your study include a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date

Screening started in 1991, but data before that date are obtained from national and local registries

Q10a. ii) Please enter the data collection end date

Currently we have follow-up data until Dec 31, 2014

Q10a. iii) Is data collection for this study

Data analysis ongoing|Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Q11. Is data collected

Through links to other records or registers (e.g dental records, police records etc)

Other please specify here

National medical and population registers (SoS, SCB), Tax authority etc

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

No

Q13a. Please give information on the format and availability of data stored in a database (1)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (2)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (3)

Database on spreadsheet (e.g. excel)

% available

100

Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available
Other (please specify)
% available
Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (3)

Data held on computer based records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available
Please specify language used

English, Swedish

Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource|Access committee mechanism|Local/ regional access|National access|International access|Access to industry|Access for pilot studies permitted|Applicant needs to provide separate external ethics approval|Resource has own ethics approval so usually no need for separate external ethics approval

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors: blood derivatives|Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?

Secondary samples:(derivatives of primary samples)|Secondary samples: plasma|Secondary samples: DNA

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
Sweden

Diseases:
Alzheimer's disease & other dementias, Parkinson's disease & PD-related disorders

Years:
2016

Database Categories:
N/A

Database Tags:
N/A